BiomeNrich™ Targets Southeast Asia with Wellness-Boosting Bifido

SEOUL, South Korea, July 9, 2025 /PRNewswire/ -- As Southeast Asia's health and wellness market rapidly evolves, consumer expectations are shifting toward multifunctional solutions that go beyond basic digestion. Gut health is now understood as the foundation for immune support, skin clarity, mental balance, and even healthy aging. Among the key microbiome species for gut health, Bifidobacterium bifidum and B. animalis subsp. lactis have emerged as central players in this transformation.

BiomeNrich PRO G814, PRO G952

Recognizing this growing need for targeted probiotic innovation, CJ BIO has introduced two new Bifidobacterium strains under its advanced BiomeNrich™ PRO G814 (Bifidobacterium bifidum) and PRO G952 (B. animalis subsp. lactis).

Unveiled at Vitafoods Europe 2025, these two human-origin strains reflect CJ BIO's strategy to provide diverse solutions for customers seeking innovative probiotic ingredients for gut health. Their introduction brings new scientific diversity and formulation potential to Southeast Asian partners seeking to meet the region's growing demand for premium gut health ingredients.

The inclusion of Bifidobacterium introduces new clinical potential — especially in targeting life stage –specific microbiome challenges such as age-related declines in Bifidobacterium levels, which are associated with gastrointestinal discomfort.

BiomeNrich™ PRO G814 and PRO G952 are rooted in over 30 years of scientific research, supported by clinical trials and historical use. The safety of the products has been recognized by the U.S. FDA through GRAS (Generally Recognized as Safe) and NDIN (New Dietary Ingredient Notification), as well as being listed in the QPS (Qualified Presumption of Safety) in Europe. Additionally, their usability is supported by certifications, including Halal and Kosher status, catering to religious needs in the Southeast Asian market. These additional measures have been taken to ensure seamless integration into a wide range of finished products for dietary supplements and functional foods.

Beyond safety and regulatory readiness, these strains offer unique advantages in formulation and health outcomes. What sets them apart is not only their clinical performance, but also their origin and quality control. Both strains are isolated from healthy, breastfed infants and selected for their ability to:

• Strongly adhere to human intestinal epithelial cells
• Survive in high-acid and bile conditions
• Deliver measurable benefits for digestive and immune functions

BiomeNrich™ reflects our commitment to holistic, gut-organ axis innovation — with these new Bifidobacterium strains representing our next step in enabling partners to formulate with purpose and precision.

For more details on clinical performance, origin, application formats, and formulation compatibility:
https://online.cjbio.net/bnr_bifido_pr